Nina Niu Sanford: 4 Trials Asking the Same Question About Adjuvant IO in “High Risk” HCC
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X by Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, adding:
“What’s also interesting here is there are essentially 4 trials asking the same question regarding: adjuvant IO in ‘high risk’ HCC.
And if just 1 is positive (and for surrogate RFS endpoint), IO will be approved in spite of all the other negative data.”
Quoting Mark Yarchoan‘s post:
“More disappointing news in HCC:
Adjuvant pembrolizumab failed to beat surveillance in the global P3 KEYNOTE-937 trial (NCT03867084). Merck disclosed the negative result quietly in an SEC filing. Not unexpected after IMbrave050.”
More posts featuring Nina Niu Sanford and Mark Yarchoan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023